Background: Data on cognitive impairment after acute intracerebral hemorrhage (ICH) are limited. This study is aimed at determining the frequency and predictors of cognitive impairment among participants of the pilot phase, Intensive Blood Pressure (BP) Reduction in Acute Cerebral Hemorrhage Trial (INTERACT1). Methods: INTERACT1 was an open randomized trial of early intensive (target systolic BP <140 mm Hg) compared with contemporaneous guideline-recommended BP lowering in 404 patients with elevated systolic BP (150-220 mm Hg) within 6 h of ICH onset. Cognitive impairment was defined by scores ≤24 on the Mini-Mental State Examination (MMSE) assessed by interview on followup at 90 days. Results: A total of 231 (64.5%) of 358 90-day survivors had MMSE scores for analyses, and 75 (32.5%) had cognitive impairment. In multivariable analysis, older age (OR 2.48, 95% CI 1.73-3.56 per 10-year increase; p < 0.001), female sex (OR 2.06, 95% CI 1.00-4.23; p = 0.049), prior ICH (OR 2.87, 95% CI 1.08-7.65; p = 0.035), high baseline National Institute of Health Stroke Scale score (OR 1.06, 95% CI 1.00-1.13; p = 0.044), and high mean systolic BP over the first 24 h post-randomization (OR 1.34, 95% CI 1.07-1.68/10 mm Hg increase; p = 0.011) were independently associated with cognitive impairment. Conclusions: One third of patients have significant cognitive impairment early after ICH, which is more frequent in the elderly, females, those with prior ICH, and more severe initial neurological deficit and with persistently high early systolic BP.
Introduction
Post-stroke cognitive impairment is common, carries a poor prognosis, and often poorly recognized [1] . Intracerebral hemorrhage (ICH) is well recognized as a serious type of stroke with high burden of premature death and Clinical Trial Registration-URL: http://www.clinicaltrials.gov. Unique identifier: NCT00226096.
Cerebrovasc Dis 2017;44:320-324 DOI: 10.1159/000481443 disability [2] . Recent studies reported that there is a high rate of long-term cognitive impairment or new-onset dementia, up to 4 years after ICH [3] [4] [5] . However, data on early cognitive impairment after ICH are scarce [6] . The pilot phase of the intensive blood pressure (BP) reduction in acute cerebral hemorrhage trial (INTERACT1) was an international, open, randomized controlled trial that investigated the effects of early intensive BP lowering in patients with acute spontaneous ICH [7] . Herein, we report the frequency and predictors of early cognitive impairment, which was assessed among surviving participants at 90-days follow-up.
Methods
The design and main results of INTERACT1 are outlined elsewhere [7] . In brief, 404 adult patients with CT-confirmed ICH within 6 h of onset and elevated systolic BP (150-220 mm Hg) were randomly assigned to receive intensive (target systolic BP <140 mm Hg within 1 h) or contemporaneous guideline-recommended (<180 mm Hg) BP lowering treatment. The study protocol was approved by the appropriate Ethics Committee at each participating site, and written informed consent was obtained directly from the patient or an appropriate surrogate. INTERACT1 is registered at Clinical Trials.gov (NCT00226096).
Demographics, clinical characteristics, and medical history including current medications, were recorded at the time of enrolment. Stroke severity was measured using the Glasgow Coma Scale and National Institutes of Health Stroke Scale (NIHSS) at baseline, 24 h, and at day 7 (or earlier upon discharge from hospital). CT scans were performed according to standardized techniques at baseline and centrally analyzed for volume and location of ICH. Cognitive impairment was defined by scores ≤24 on the MiniMental State Examination (MMSE) assessed at 90 days [8] . A sensitivity analysis was performed among patients with severe cognitive impairment (MMSE ≤18).
Multivariable logistic regression was used to determine the predictors of cognitive impairment. All the variables with p < 0.2 in the univariate analysis were included in multivariable analyses, with the full model developed by successively removing all nonsignificant covariates until all those remaining were statistically significant (p < 0.05). Data are reported as OR with 95% CI. SAS version 9.3 (SAS Institute, Cary, NC, USA) was used for analyses.
Results
Of the 404 INTERACT1 participants, 46 patients died within 3 months and 127 patients without an MMSE score were excluded. Thus, 231 (64.5%) ICH survivors (median [IQR] age 64 [52-72] years, 35.5% female) with 90-days MMSE scores were included in the analyses. Table 1 shows that included patients were clinically less severe (higher Glasgow Coma Scale scores, lower NIHSS scores), and had smaller hematoma volume, less intraventricular extension, and lower diastolic BP at baseline. Table 2 shows the univariate predictors of cognitive impairment (MMSE score ≤24), present in 75 (32.5%) patients, such as older age, female, history of ICH or ischemic stroke, higher baseline NIHSS score, less intraventricular extension , lower diastolic BP at baseline, and higher mean systolic BP over the first 24 h post-randomization. The variables were similar in sensitivity analyses using a MMSE cut-off of 18 (online suppl. Table 1 , see www.karger.com/doi/10.1159/000481443). In multivariable analyses, older age (OR 2.48, 95% CI 1.73-3.56 per 10-year increase; p < 0.001), female (OR 2.06, 95% CI 1.00-4.23; p = 0.049), prior ICH (OR 2.87, 95% CI 1.08-7.65; p = 0.035), higher baseline NIHSS score (OR 1.06, 95% CI 1.00-1.13; p = 0.044), and higher systolic BP over the first 24 h post-randomization (OR 1.34, 95% CI 1.07-1.68 per 10 mm Hg increase; p = 0.011) were independently associated with cognitive impairment (Table 2) .
Discussion
In the secondary analysis of the INTERACT1 study, over one third of ICH survivors had significant cognitive impairment, defined by scores ≤24 on the MMSE at 90-days follow-up. The independent variables associated with this adverse outcome were older age, female, prior ICH history, more severe ICH (higher NIHSS scores), and higher systolic BP over the first 24 h.
The reported rate of long-term cognitive impairment up to 4 years after ICH varies widely from 23 to 61% [3-5, 9, 10] , which may be due to different patient population or the definition of cognitive impairment. Only one small study (n = 29) found that 27.6% of the patients developed cognitive impairment at 3 months after ICH [6] . Our study with bigger sample size of 231 ICH patients found a similar rate (32.5%) at 90 days after ICH. The data suggest a process of ongoing cognitive impairment already present as early as 3 months after ICH.
In the present study, we found older age, female, and severe stroke as predictors of cognitive impairment, which is in line with previous studies [3, 5, [11] [12] [13] . A single center cohort study in US with 738 ICH patients reported that larger hematoma volume was a strong independent predictor of new-onset dementia within 6 months after ICH [4] . Our analysis results indirectly support this finding, as shown by the independent associations between greater NIHSS score and higher SBP, DOI: 10.1159/000481443 which may be associated with large hematoma [14] . However, our study may have failed to detect an association between hematoma volume and cognitive impairment due to decreased study power from exclusion of patients with larger hematoma volume (the median of hematoma volume is 19.4 mL in the US study [4] , while the hematoma volume is only 8.5 mL in our study). We had tried to account for hematoma location by including "lobar location" in our analysis, as suggested by previous studies that indicated a strong relationship between lobar hemorrhage and new-onset dementia [3, 4] . However, lobar hemorrhage was not associated with cognitive impairment at 90 days in our study. The variations in study results may be due to differences in patient characteristics; more than 30% of patients were with lobar hemorrhage in the previous studies [3, 4] compared to only 8.1% in our study.
Interestingly, our study further supports the adverse consequences of the immediate hypertensive response in ICH, showing that high mean systolic BP over the first 24 h was related to cognitive impairment. This is in line with related evidence of hypertension with both vascular dementia and Alzheimer's disease [15] , although longterm BP lowering has not shown any impact on the risk of dementia [16, 17] . The association between BP lowering treatment and risk of cognitive impairment is complex and confounded by an interaction with stroke prevention [18] . Limitations of this study include small sample size, selected group of patients, and large hematoma being underrepresented related to its inclusion in a clinical trial and of missing MMSE outcome. Furthermore, we did not have the ability to assess the impact of ICH on pre-existing cognitive impairment or in relation to education level, which is associated with cognitive impairment after stroke and acknowledge that the MMSE is a crude measure of cognitive functioning.
Conclusions
In summary, our study has shown that there is a high frequency of cognitive impairment in the first few months after the onset of ICH, which is related not just to established factors, such as age, sex, and severity of the initial neurological deficit, but also to persistent systolic BP elevation over the first 24 h.
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